Synopsis: Several stocks are potential entrants to the F&O ban list, restricting derivative trading to curb speculation. This limits leveraged positions, may reduce volatility, and …
SYNOPSIS: Morgan Stanley maintains an ‘Underweight’ rating on two chemical stocks, citing rising R-32 capacity, potential 25 percent price correction, and earnings sensitivity to refrigerant …
Synopsis: A leading brokerage maintained a ‘Buy’ rating with a Rs 87 target, implying 23% upside from Rs 70.85. A ₹590 crore fraud at one …
SYNOPSIS: Promoter of one of the leading global manufacturers and exporters of PVC-based products, Fairpoint Tradecom LLP, pledged an additional 3 lakh shares, increasing total …
Synopsis: Eris Lifesciences jumps 4% after partnering with Natco Pharma to launch Semaglutide in India by March 2026, strengthening its diabetes portfolio and leadership in …
Synopsis: These debt-free stocks are trading at attractive P/Es, significantly below their respective industry averages, highlighting potential undervaluation and strong financial health for investors to …
Synopsis: Several stocks under Rs. 100 reported extraordinary Q3FY26 EPS growth up to 1,900 percent, driven by strong revenue gains, sequential profit improvements, and robust …
Synopsis: CRISIL expects India’s two-wheeler volumes to exceed 29 million in FY27, led by rural demand, exports and premiumisation, including companies that have recorded volume …
Synopsis: The Supreme Court’s decision to strike down Trump-era tariffs could trigger up to USD 175 billion in refunds, largely benefiting companies rather than consumers. …
Synopsis: The ₹380 crore IPO, priced at ₹367–₹386, opens February 24–26, 2026, with listing slated for March 4. Proceeds will fund 15 new stores and …